irbesartan (BioDeep_00000397555)

Main id: BioDeep_00000001543

 


代谢物信息卡片


irbesartan

化学式: C25H28N6O (428.2324478)
中文名称: 伊贝沙坦
谱图信息: 最多检出来源 Homo sapiens(blood) 9.09%

分子结构信息

SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
InChI: InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

描述信息

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1074
CONFIDENCE standard compound; INTERNAL_ID 2094
CONFIDENCE standard compound; INTERNAL_ID 8187
Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1].

同义名列表

3 个代谢物同义名

irbesartan; SR-47436; BMS-186295



数据库引用编号

53 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Zhenjie Chen, Jiajia Bai, Liwen Niu. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The New England journal of medicine. 2024 Mar; 390(12):1154. doi: 10.1056/nejmc2401126. [PMID: 38507768]
  • Nural Pastacı Özsobacı, Metehan Karataş, Matem Tunçdemir, Derviş Özcelik. Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker on oxidative stress and metabolism of elements in kidney of STZ-induced diabetic rats. Archives of biochemistry and biophysics. 2024 Jan; 751(?):109851. doi: 10.1016/j.abb.2023.109851. [PMID: 38065251]
  • Jinxi Zhao, Shidong Wang, Xiaoran Li, Guangde Zhang, Yuan Xu, Xianling Zheng, Jian Guo, Zhenxian Zhang. A Prospective, Multicentered, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Keluoxin Capsules in the Treatment of Microalbuminuria in Patients with Type 2 Early Diabetic Kidney Disease. Journal of integrative and complementary medicine. 2023 Sep; ?(?):. doi: 10.1089/jicm.2022.0809. [PMID: 37733303]
  • Haozhen Wang, Ziyin Lu, Yang Li, Ting Liu, Linlin Zhao, Tianqi Gao, Xiuli Lu, Bing Gao. Virtual Screening of Novel 24-Dehydroxysterol Reductase (DHCR24) Inhibitors and the Biological Evaluation of Irbesartan in Cholesterol-Lowering Effect. Molecules (Basel, Switzerland). 2023 Mar; 28(6):. doi: 10.3390/molecules28062643. [PMID: 36985615]
  • Rui Li, Chuanzhou Liang, Sif B Svendsen, Vaidotas Kisielius, Kai Bester. Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism. Water research. 2023 Feb; 229(?):119352. doi: 10.1016/j.watres.2022.119352. [PMID: 36450176]
  • Narendar Dudhipala, Swetha Ettireddy, Ahmed Adel Ali Youssef, Goverdhan Puchchakayala. Development and In vivo Pharmacokinetic and Pharmacodynamic Evaluation of an Oral Innovative Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan Formulation for Enhanced Bioavailability. Nanotheranostics. 2023; 7(1):117-127. doi: 10.7150/ntno.78102. [PMID: 36593793]
  • Y U Lu, Tsutomu Miyamoto, Hodaka Takeuchi, Fumi Tsunoda, Naoki Tanaka, Tanri Shiozawa. PPARα activator irbesartan suppresses the proliferation of endometrial carcinoma cells via SREBP1 and ARID1A. Oncology research. 2023; 31(3):239-253. doi: 10.32604/or.2023.026067. [PMID: 37305395]
  • Pei-Ying Pai, Yi-Yuan Lin, Shao-Hong Yu, Ching-Yuang Lin, Yi-Fan Liou, Xu-Bo Wu, James K S Wong, Chih-Yang Huang, Shin-Da Lee. Angiotensin II receptor blocker irbesartan attenuates sleep apnea-induced cardiac apoptosis and enhances cardiac survival and Sirtuin 1 upregulation. Sleep & breathing = Schlaf & Atmung. 2022 09; 26(3):1161-1172. doi: 10.1007/s11325-021-02499-6. [PMID: 34626328]
  • Jing Zhao, Isabelle Tostivint, Lingdong Xu, Jihan Huang, Laetitia Gambotti, Jean-Jacques Boffa, Min Yang, Ling Wang, Zhuxing Sun, Xiaolan Chen, Amélie Liou-Schischmanoff, Alain Baumelou, Teng Ma, Guoyuan Lu, Ling Li, Dai Chen, Laurence Piéroni, Bingkai Liu, Xiao Qin, Weiming He, Yuejuan Wang, Harvest F Gu, Wei Sun. Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial. Diabetes care. 2022 07; 45(7):e113-e115. doi: 10.2337/dc22-0607. [PMID: 35613364]
  • İlter İlhan, Halil Aşçi, Nursel Hasseyid, Hatice Kubra Doğan, Şerife Ağirca, Melike Altintaş, Muhammet Yusuf Tepebasi. Irbesartan decreased mitochondrial stress related apoptosis in cisplatin induced acute kidney injury via regulating BCL-2/BAX signaling. Molecular biology reports. 2022 Jul; 49(7):6125-6133. doi: 10.1007/s11033-022-07403-3. [PMID: 35366178]
  • Jian Gao, Zheng Liang, Fei Zhao, Xiaojing Liu, Ning Ma. Triptolide inhibits oxidative stress and inflammation via the microRNA-155-5p/brain-derived neurotrophic factor to reduce podocyte injury in mice with diabetic nephropathy. Bioengineered. 2022 05; 13(5):12275-12288. doi: 10.1080/21655979.2022.2067293. [PMID: 35603354]
  • Shaoqi Zuo, Haoyu Meng, Jiahui Liang, Huajun Zhen, Ying Zhu, Yanbin Zhao, Kun Zhang, Jiayin Dai. Residues of Cardiovascular and Lipid-Lowering Drugs Pose a Risk to the Aquatic Ecosystem despite a High Wastewater Treatment Ratio in the Megacity Shanghai, China. Environmental science & technology. 2022 02; 56(4):2312-2322. doi: 10.1021/acs.est.1c05520. [PMID: 35129343]
  • F P Zhang, X Jiang. The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2022 Feb; 73(1):. doi: 10.26402/jpp.2022.1.06. [PMID: 35639038]
  • Sally E Abu-Risha, Mai A Mousa, Alaa E Elsisi. Protective role of irbesartan against cyclophosphamide-induced testicular damage in rats via up-regulating PPAR-γ signaling and ameliorating NF-κB/NLRP3/IL-18 inflammatory axis. Life sciences. 2022 Jan; 289(?):120218. doi: 10.1016/j.lfs.2021.120218. [PMID: 34890588]
  • Narendar Dudhipala, Swetha Ettireddy, Ahmed Adel Ali Youssef, Goverdhan Puchchakayala. Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization. Molecules (Basel, Switzerland). 2021 Dec; 26(24):. doi: 10.3390/molecules26247538. [PMID: 34946619]
  • Di Zhang, Qi-Fang Huang, Yan Li, Ji-Guang Wang. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Blood pressure monitoring. 2021 Dec; 26(6):413-418. doi: 10.1097/mbp.0000000000000554. [PMID: 34128490]
  • Junting Weng, Min Chen, Rongjie Guo, Shuzhen Yang, Danjuan Liu, Dexiang Fang. The antihypertensive effect of irbesartan in spontaneously hypertensive rats is associated with improvement of the leptin-adiponectin imbalance. Adipocyte. 2021 12; 10(1):101-107. doi: 10.1080/21623945.2021.1886409. [PMID: 33570444]
  • Ann B Moser, Yanqiu Liu, Xiaohai Shi, Ulrike Schrifl, Shandi Hiebler, Ali Fatemi, Nancy E Braverman, Steven J Steinberg, Paul A Watkins. Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids. Journal of cellular biochemistry. 2021 10; 122(10):1337-1349. doi: 10.1002/jcb.30014. [PMID: 34056752]
  • Yiliyaer Nijiati, Lianlian Shan, Tao Yang, Maiwulanijiang Yizibula, Ainiwaer Aikemu. A 1H NMR spectroscopic metabolomic study of the protective effects of irbesartan in a rat model of chronic mountain sickness. Journal of pharmaceutical and biomedical analysis. 2021 Sep; 204(?):114235. doi: 10.1016/j.jpba.2021.114235. [PMID: 34252817]
  • Hao Zhou, Wenyue Li, Ling Sun, Wenfang Li, Qian Liu. A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. Biomedical chromatography : BMC. 2021 Sep; 35(9):e5144. doi: 10.1002/bmc.5144. [PMID: 33880775]
  • M Piazza, N M J Hanssen, F Persson, J L Scheijen, M P H van de Waarenburg, M M J van Greevenbroek, P Rossing, P Hovind, C D A Stehouwer, H-H Parving, C G Schalkwijk. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. Diabetic medicine : a journal of the British Diabetic Association. 2021 09; 38(9):e14405. doi: 10.1111/dme.14405. [PMID: 32961617]
  • Yiliyaer Nijiati, Tao Yang, Mutalifu Aimaiti, Dilinuer Maimaitiyiming, Ainiwaer Aikemu. Irbesartan ameliorates chronic mountain sickness in a rat model via the cholesterol metabolism: An iTRAQ -based proteomics analysis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 Sep; 141(?):111802. doi: 10.1016/j.biopha.2021.111802. [PMID: 34147903]
  • Y Nijiati, D Maimaitiyiming, T Yang, H Li, A Aikemu. Research on the improvement of oxidative stress in rats with high-altitude pulmonary hypertension through the participation of irbesartan in regulating intestinal flora. European review for medical and pharmacological sciences. 2021 Jul; 25(13):4540-4553. doi: 10.26355/eurrev_202107_26247. [PMID: 34286497]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Alokkumar S Pathak, Mauricio Rojas, George A Stouffer. Expression of Cyr61 in ApoE-/- mice with chronic unilateral renal artery ligation. Scientific reports. 2021 02; 11(1):3606. doi: 10.1038/s41598-021-81646-1. [PMID: 33574403]
  • Rigas G Kalaitzidis, Olga Balafa, Evangelia Dounousi, Dimitrios Stagikas, Vasilios Tsimihodimos. Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients. Current vascular pharmacology. 2021; 19(5):565-571. doi: 10.2174/1570161119666201120160104. [PMID: 33222674]
  • Daniela Volonte, Morgan Sedorovitz, Victoria E Cespedes, Maria L Beecher, Ferruccio Galbiati. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic K-Ras. The Journal of biological chemistry. 2021 Jan; 296(?):100242. doi: 10.1074/jbc.ra120.015188. [PMID: 33380422]
  • Ibrahim A Darwish, Hany W Darwish, Ahmed H Bakheit, Hamad M Al-Kahtani, Zahi Alanazi. Irbesartan (a comprehensive profile). Profiles of drug substances, excipients, and related methodology. 2021; 46(?):185-272. doi: 10.1016/bs.podrm.2020.07.004. [PMID: 33461698]
  • Ling-Na Fang, Shao Zhong, Li-Ji Huang, Bing Lu, Li-Wen Shen, Feng-Yan Tang, He-Ping Sun, Li Zhang. Protective Effect of Irbesartan by Inhibiting ANGPTL2 Expression in Diabetic Kidney Disease. Current medical science. 2020 Dec; 40(6):1114-1120. doi: 10.1007/s11596-020-2304-z. [PMID: 33263178]
  • Bin Dai, Zi-Zhang Wang, Hui Zhang, Meng-Xiao Han, Guo-Xing Zhang, Jing-Wei Chen. Antihypertensive properties of a traditional Chinese medicine GAO-ZI-YAO in elderly spontaneous hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 Nov; 131(?):110739. doi: 10.1016/j.biopha.2020.110739. [PMID: 32932045]
  • Dan Li, Bo Li, Li-Xia Peng, Rong Liu, Nan Zeng. Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis. Clinical therapeutics. 2020 11; 42(11):2196-2212. doi: 10.1016/j.clinthera.2020.09.013. [PMID: 33158581]
  • Christian D Peters, Krista D Kjaergaard, Kent L Christensen, Bo M Bibby, Bente Jespersen, Jens D Jensen. High-sensitivity Troponin T in hemodialysis patients: a randomized placebo-controlled sub-study investigating angiotensin-II-blockade, variation over time and associations with clinical outcome. BMC nephrology. 2020 10; 21(1):452. doi: 10.1186/s12882-020-02103-1. [PMID: 33115436]
  • Gan Mi Wang, Liang Jin Li, Wen Lu Tang, James M Wright. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. The Cochrane database of systematic reviews. 2020 10; 10(?):CD012569. doi: 10.1002/14651858.cd012569.pub2. [PMID: 33089502]
  • Yong Zhong, Rong Tang, Yang Lu, Wei Wang, Chenggen Xiao, Ting Meng, Xiang Ao, Xiaozhao Li, Ling Peng, Patrick Kwadwo Nuro-Gyina, Qiaoling Zhou. Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. International immunopharmacology. 2020 Oct; 87(?):106789. doi: 10.1016/j.intimp.2020.106789. [PMID: 32683300]
  • Eleni Karatza, Vangelis Karalis. Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020 Oct; 153(?):105498. doi: 10.1016/j.ejps.2020.105498. [PMID: 32736091]
  • Naoki Nakagawa, Nobuyuki Sato, Yasuaki Saijo, Hideo Morimoto, Satoshi Koyama, Yuji Ogawa, Kazumi Uekita, Junichi Maruyama, Takafumi Ohta, Yasuhiro Nakamura, Toshiharu Takeuchi, Naoyuki Hasebe. Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study). Journal of clinical hypertension (Greenwich, Conn.). 2020 09; 22(9):1577-1584. doi: 10.1111/jch.13977. [PMID: 32762115]
  • Zhanying Liu, Lin Zhang, Ruijie Zhai, Jiarong Lan. Comparison of Irbesartan and Benazepril Hydrochloride on Urine Protein Reduction in Chronic Glomerulonephritis. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2020 Sep; 30(9):1000-1001. doi: 10.29271/jcpsp.2020.09.1000. [PMID: 33036695]
  • Zeid A ALOthman, Khalid M Alsheetan, Hassan Y Aboul-Enein, Imran Ali. Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Jun; 1146(?):122125. doi: 10.1016/j.jchromb.2020.122125. [PMID: 32371329]
  • Aimin Tan, Xuan Gui, Molly Wong, Hui Deng, Guifen Gu, Constantine Fanaras, John C Fanaras. Simultaneous quantification of candesartan and irbesartan in rabbit eye tissues by liquid chromatography-tandem mass spectrometry. Biomedical chromatography : BMC. 2020 May; 34(5):e4808. doi: 10.1002/bmc.4808. [PMID: 32100318]
  • Juyoung Shin, Hun-Sung Kim, Tong Min Kim, Hyunah Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon. The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients. Basic & clinical pharmacology & toxicology. 2020 May; 126(5):424-431. doi: 10.1111/bcpt.13369. [PMID: 31765038]
  • Navpreet Kaur, Poonam Singh Thakur, Ganesh Shete, Rahul Gangwal, Abhay T Sangamwar, Arvind Kumar Bansal. Understanding the Oral Absorption of Irbesartan Using Biorelevant Dissolution Testing and PBPK Modeling. AAPS PharmSciTech. 2020 Mar; 21(3):102. doi: 10.1208/s12249-020-01643-x. [PMID: 32152915]
  • Miao Ye, Wen Xu, Da-Qing He, Xian Wu, Wen-Fang Lai, Xiao-Qin Zhang, Yu Lin, Wei Xu, Xu-Wen Li. Dammarane-Type Triterpenoids from the Roots of Rhus chinensis and Their Preventive Effects on Zebrafish Heart Failure and Thrombosis. Journal of natural products. 2020 02; 83(2):362-373. doi: 10.1021/acs.jnatprod.9b00857. [PMID: 32031812]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Mohamed Saleh Elgawish, Moustafa K Soltan, Mahmoud M Sebaiy. An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. Journal of pharmaceutical and biomedical analysis. 2019 Sep; 174(?):226-234. doi: 10.1016/j.jpba.2019.05.069. [PMID: 31181484]
  • Weizhong Huangfu, Fuhou Chang, Minjie Wang, Ruiying Gao. ALDH2 improved irbesartan treatment efficacy among rats with hypertension. Pakistan journal of pharmaceutical sciences. 2019 Sep; 32(5(Special)):2495-2499. doi: . [PMID: 31894041]
  • Rohit Ramchandra, Daniel T Xing, Marcus Matear, Gavin Lambert, Andrew M Allen, Clive N May. Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure. American journal of physiology. Regulatory, integrative and comparative physiology. 2019 09; 317(3):R386-R396. doi: 10.1152/ajpregu.00026.2019. [PMID: 31241978]
  • Barbara Ruggiero, Matias Trillini, Lida Tartaglione, Silverio Rotondi, Elena Perticucci, Rocco Tripepi, Carolina Aparicio, Veruska Lecchi, Annalisa Perna, Francesco Peraro, Davide Villa, Silvia Ferrari, Antonio Cannata, Sandro Mazzaferro, Francesca Mallamaci, Carmine Zoccali, Antonio Bellasi, Mario Cozzolino, Giuseppe Remuzzi, Piero Ruggenenti, Donald E Kohan. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019 09; 74(3):338-350. doi: 10.1053/j.ajkd.2019.01.029. [PMID: 31027883]
  • Jasper Tromp, Li Shen, Pardeep S Jhund, Inder S Anand, Peter E Carson, Akshay S Desai, Christopher B Granger, Michel Komajda, Robert S McKelvie, Marc A Pfeffer, Scott D Solomon, Lars Køber, Karl Swedberg, Michael R Zile, Bertram Pitt, Carolyn S P Lam, John J V McMurray. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2019 08; 74(5):601-612. doi: 10.1016/j.jacc.2019.05.052. [PMID: 31370950]
  • Ying Zuo, Ting Li, Zhen Lei. Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials. Pharmacological research. 2019 08; 146(?):104286. doi: 10.1016/j.phrs.2019.104286. [PMID: 31152787]
  • Jin Hee Jeong, Coral Hanevold, Ryan A Harris, Gaston Kapuku, Jennifer Pollock, David Pollock, Gregory Harshfield. Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans. Journal of clinical hypertension (Greenwich, Conn.). 2019 08; 21(8):1191-1199. doi: 10.1111/jch.13625. [PMID: 31328876]
  • Nermin T El-Said, Eman A Mohamed, Ragia A Taha. Irbesartan suppresses cardiac toxicity induced by doxorubicin via regulating the p38-MAPK/NF-κB and TGF-β1 pathways. Naunyn-Schmiedeberg's archives of pharmacology. 2019 06; 392(6):647-658. doi: 10.1007/s00210-019-01624-3. [PMID: 30734091]
  • G-D Ren, Y -Y Cui, W-L Li, F-F Li, X-Y Han. Research on cardioprotective effect of irbesartan in rats with myocardial ischemia-reperfusion injury through MAPK-ERK signaling pathway. European review for medical and pharmacological sciences. 2019 Jun; 23(12):5487-5494. doi: 10.26355/eurrev_201906_18218. [PMID: 31298402]
  • Xingang Zhao, Dongbin Yang, Weiwei Xu, Wen Xu, Zhengdong Guo. Effect of Irbesartan on Oxidative Stress and Serum Inflammatory Factors in Renal Tissues of Type 2 Diabetic Rats. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2019 May; 29(5):422-425. doi: 10.29271/jcpsp.2019.05.422. [PMID: 31036110]
  • Ryoko Umebayashi, Haruhito A Uchida, Yuka Okuyama, Yuki Kakio, Yoshihisa Hanayama, Kenichi Shikata, Jun Wada. The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2019 May; 24(3):255-261. doi: 10.1080/1354750x.2018.1548033. [PMID: 30444137]
  • Zebun Nisa, Syed Imran Ali, Mehwish Rizvi, Maqsood Ahmed Khan, Rafi Akhter Sultan, Rasheeda Fatima, Najma Shaheen, Farya Zafar, Sadia Suri Kashif, Najeeb Khatian. Development and validation of reverse phase HPLC method for determination of angiotensin receptor blocking agent irbesartan in plasma. Pakistan journal of pharmaceutical sciences. 2019 Mar; 32(2 (Supplementary)):853-858. doi: NULL. [PMID: 31103982]
  • Yiwen Cui, Katsuhisa Masaki, Xu Zhang, Ryo Yamasaki, Takayuki Fujii, Hidenori Ogata, Shotaro Hayashida, Hiroo Yamaguchi, Fuminori Hyodo, Hinako Eto, Sachiko Koyama, Kyoko Iinuma, Tomomi Yonekawa, Takuya Matsushita, Mari Yoshida, Kazunori Yamada, Mitsuhiro Kawano, Marie Malissen, Bernard Malissen, Junichi Kira. A novel model for treatment of hypertrophic pachymeningitis. Annals of clinical and translational neurology. 2019 03; 6(3):431-444. doi: 10.1002/acn3.715. [PMID: 30911567]
  • Izabela Zakrocka, Katarzyna M Targowska-Duda, Artur Wnorowski, Tomasz Kocki, Krzysztof Jóźwiak, Waldemar A Turski. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro. Naunyn-Schmiedeberg's archives of pharmacology. 2019 02; 392(2):209-217. doi: 10.1007/s00210-018-1572-7. [PMID: 30370429]
  • Gui-Yun Jiang, Qun Li, Yun-Xiang Lv. Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD. International journal of chronic obstructive pulmonary disease. 2019 ; 14(?):73-80. doi: 10.2147/copd.s186872. [PMID: 30587963]
  • Matthias Hoffmann, Xinyu Chen, Mitsuru Hirano, Kenji Arimitsu, Hiroyuki Kimura, Takahiro Higuchi, Michael Decker. 18 F-Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging. ChemMedChem. 2018 12; 13(23):2546-2557. doi: 10.1002/cmdc.201800638. [PMID: 30430750]
  • Mélodie Schmitz, Mahaut Beghin, Syaghalirwa N M Mandiki, Katherine Nott, Michaël Gillet, Sébastien Ronkart, Christelle Robert, Sébastien Baekelandt, Patrick Kestemont. Environmentally-relevant mixture of pharmaceutical drugs stimulates sex-steroid hormone production and modulates the expression of candidate genes in the ovary of juvenile female rainbow trout. Aquatic toxicology (Amsterdam, Netherlands). 2018 Dec; 205(?):89-99. doi: 10.1016/j.aquatox.2018.10.006. [PMID: 30347285]
  • Eman A Mohamed, Hebatalla I Ahmed, Heba S Zaky. Protective effect of irbesartan against doxorubicin-induced nephrotoxicity in rats: implication of AMPK, PI3K/Akt, and mTOR signaling pathways. Canadian journal of physiology and pharmacology. 2018 Dec; 96(12):1209-1217. doi: 10.1139/cjpp-2018-0259. [PMID: 30351976]
  • Shengnan Hu, Jun Cheng, Justin Weinstock, Xiu Fan, Scott A Venners, Yi-Hsiang Hsu, Suwen Wu, Faming Pan, Xiangdong Zha, Jinlu Sun, Shanqun Jiang, Xiping Xu. A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension. Journal of human hypertension. 2018 11; 32(11):781-788. doi: 10.1038/s41371-018-0119-1. [PMID: 30283089]
  • Howard Trachtman, Peter Nelson, Sharon Adler, Kirk N Campbell, Abanti Chaudhuri, Vimal Kumar Derebail, Giovanni Gambaro, Loreto Gesualdo, Debbie S Gipson, Jonathan Hogan, Kenneth Lieberman, Brad Marder, Kevin Edward Meyers, Esmat Mustafa, Jai Radhakrishnan, Tarak Srivastava, Miganush Stepanians, Vladimír Tesar, Olga Zhdanova, Radko Komers. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology : JASN. 2018 11; 29(11):2745-2754. doi: 10.1681/asn.2018010091. [PMID: 30361325]
  • Matthew James, Braden Manns. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease. Circulation. 2018 10; 138(15):1515-1518. doi: 10.1161/circulationaha.118.036523. [PMID: 30354525]
  • Richard Haynes, Parminder K Judge, Natalie Staplin, William G Herrington, Benjamin C Storey, Angelyn Bethel, Louise Bowman, Nigel Brunskill, Paul Cockwell, Michael Hill, Philip A Kalra, John J V McMurray, Maarten Taal, David C Wheeler, Martin J Landray, Colin Baigent. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018 10; 138(15):1505-1514. doi: 10.1161/circulationaha.118.034818. [PMID: 30002098]
  • Ahmed M Kabel, Abdulaziz A Alzahrani, Nawaf M Bawazir, Rayan O Khawtani, Hany H Arab. Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2018 Aug; 24(8):623-631. doi: 10.1016/j.jiac.2018.03.010. [PMID: 29753615]
  • Qi Pei, Jun-Yan Liu, Ji-Ye Yin, Guo-Ping Yang, Shi-Kun Liu, Yi Zheng, Pan Xie, Cheng-Xian Guo, Mi Luo, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. European journal of clinical pharmacology. 2018 Aug; 74(8):1021-1028. doi: 10.1007/s00228-018-2477-6. [PMID: 29748863]
  • Ali F Abdel-Wahab, Ghazi A Bamagous, Randa M Al-Harizy, Naser A ElSawy, Naiyer Shahzad, Ibrahim A Ibrahim, Saeed S Al Ghamdi. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018 Jul; 103(?):59-66. doi: 10.1016/j.biopha.2018.03.176. [PMID: 29635129]
  • Heng Zhang, Min Tao, Pin-Fang Kang, Jian-Lu Guo, Ling Xuan, Qin Gao, Bi Tang, Lu-Jia Li, Hong-Ju Wang. [Effects of irbesartan on Notch1 signaling pathway in diabetic rats with myocardial injury]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology. 2018 May; 34(5):427-431. doi: 10.12047/j.cjap.5674.2018.097. [PMID: 30788923]
  • Yingying Chen, Peng Liu, Xia Chen, Yanan Li, Fengmei Zhang, Yangang Wang. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. The American journal of the medical sciences. 2018 05; 355(5):418-424. doi: 10.1016/j.amjms.2018.01.017. [PMID: 29753370]
  • Jamshed Haneef, Renu Chadha. Antioxidant-Based Eutectics of Irbesartan: Viable Multicomponent Forms for the Management of Hypertension. AAPS PharmSciTech. 2018 Apr; 19(3):1191-1204. doi: 10.1208/s12249-017-0930-y. [PMID: 29247285]
  • Xue-Min Zhao, Ying Zhang, Xin-Hui He, Hong-Dong Chen, Zhu-Feng Wang, Jing Guo, Xin-Miao Wang, Ze-Zheng Gao, Ji-Ping Wang, Wei Liu, Lin-Hua Zhao, Xiao-Lin Tong. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial. Trials. 2018 Mar; 19(1):200. doi: 10.1186/s13063-018-2573-z. [PMID: 29587863]
  • Jing Li, Xiaoli Fan, Qin Wang. Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report. Medicine. 2018 Mar; 97(11):e0073. doi: 10.1097/md.0000000000010073. [PMID: 29538199]
  • N G Yousif, N R Hadi, F Al-Amran, Q A Zigam. Cardioprotective effects of irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling pathway. Herz. 2018 Mar; 43(2):140-145. doi: 10.1007/s00059-017-4537-6. [PMID: 28144715]
  • Gregory A Harshfield, Coral D Hanevold, Allison Jasti, Santu Ghosh, Jennifer Pollock, David Pollock, Frank A Treiber, Yanbin Dong, Varghese George. Angiotensin II and the Natriuretic and Blood Pressure Response to Mental Stress in African Americans. Ethnicity & disease. 2018; 28(4):511-516. doi: 10.18865/ed.28.4.511. [PMID: 30405294]
  • Keisuke Okamura, Kazuyuki Shirai, Nao Totake, Tetsu Okuda, Hidenori Urata. Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. Clinical and experimental hypertension (New York, N.Y. : 1993). 2018; 40(2):99-106. doi: 10.1080/10641963.2017.1334798. [PMID: 28692311]
  • David Spirk, Sarah Noll, Michel Burnier, Stefano Rimoldi, Georg Noll, Isabella Sudano. Effect of Home Blood Pressure Monitoring on Patient's Awareness and Goal Attainment Under Antihypertensive Therapy: The Factors Influencing Results in Anti-HypertenSive Treatment (FIRST) Study. Kidney & blood pressure research. 2018; 43(3):979-986. doi: 10.1159/000490687. [PMID: 29940594]
  • Miki Hosaka, Ryusuke Inoue, Michihiro Satoh, Daisuke Watabe, Tomohiro Hanazawa, Takayoshi Ohkubo, Kei Asayama, Taku Obara, Yutaka Imai. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. Clinical and experimental hypertension (New York, N.Y. : 1993). 2018; 40(5):468-475. doi: 10.1080/10641963.2017.1403617. [PMID: 29172732]
  • . Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017 Dec; 32(12):2043-2051. doi: 10.1093/ndt/gfw321. [PMID: 27646835]
  • Jie Xing, Meitong Zang, Huixiang Liu. The application of a novel high-resolution mass spectrometry-based analytical strategy to rapid metabolite profiling of a dual drug combination in humans. Analytica chimica acta. 2017 Nov; 993(?):38-46. doi: 10.1016/j.aca.2017.08.047. [PMID: 29078953]
  • Misghina Weldegiorgis, Dick de Zeeuw, Jamie P Dwyer, Peter Mol, Hiddo J L Heerspink. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. Clinical journal of the American Society of Nephrology : CJASN. 2017 Oct; 12(10):1595-1600. doi: 10.2215/cjn.09590916. [PMID: 28923834]
  • Shigemasa Tani, Kei Asayama, Koji Oiwa, Shinsuke Harasawa, Katsuaki Okubo, Atsuhiko Takahashi, Ayumi Tanabe, Takayoshi Ohkubo, Atsushi Hirayama, Toshio Kushiro. The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. Hypertension research : official journal of the Japanese Society of Hypertension. 2017 Oct; 40(10):892-898. doi: 10.1038/hr.2017.56. [PMID: 28446804]
  • Kazuomi Kario, Naoko Tomitani, Hiroshi Kanegae, Hajime Ishii, Kazuaki Uchiyama, Kayo Yamagiwa, Toshihiko Shiraiwa, Tomohiro Katsuya, Tetsuro Yoshida, Kiyomi Kanda, Shinji Hasegawa, Satoshi Hoshide. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study. Circulation journal : official journal of the Japanese Circulation Society. 2017 Jun; 81(7):948-957. doi: 10.1253/circj.cj-17-0109. [PMID: 28321001]
  • Αdamantia S Liossi, Dimitrios Ntountaniotis, Tahsin F Kellici, Maria V Chatziathanasiadou, Grigorios Megariotis, Maria Mania, Johanna Becker-Baldus, Manfred Kriechbaum, Andraž Krajnc, Eirini Christodoulou, Clemens Glaubitz, Michael Rappolt, Heinz Amenitsch, Gregor Mali, Doros N Theodorou, Georgia Valsami, Marinos Pitsikalis, Hermis Iatrou, Andreas G Tzakos, Thomas Mavromoustakos. Exploring the interactions of irbesartan and irbesartan-2-hydroxypropyl-β-cyclodextrin complex with model membranes. Biochimica et biophysica acta. Biomembranes. 2017 Jun; 1859(6):1089-1098. doi: 10.1016/j.bbamem.2017.03.003. [PMID: 28274845]
  • Joanna Izabela Lachowicz, Valeria Marina Nurchi, Guido Crisponi, Maria de Guadalupe Jaraquemada-Pelaez, Claudia Caltagirone, Massimiliano Peana, Maria Antonietta Zoroddu, Zbigniew Szewczuk, Garth J S Cooper. Complex formation equilibria of Cu2+ and Zn2+ with Irbesartan and Losartan. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Jan; 97(?):158-169. doi: 10.1016/j.ejps.2016.11.010. [PMID: 27838251]
  • Christian D Peters, Krista D Kjaergaard, Claus H Nielsen, Kent L Christensen, Bo M Bibby, Jens D Jensen, Bente Jespersen. Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study). Hemodialysis international. International Symposium on Home Hemodialysis. 2017 01; 21(1):47-62. doi: 10.1111/hdi.12436. [PMID: 27346437]
  • Feng-Yi Hsu, Fang-Ju Lin, Huang-Tz Ou, Shih-Hui Huang, Chi-Chuan Wang. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria. Kidney & blood pressure research. 2017; 42(2):358-368. doi: 10.1159/000477946. [PMID: 28618426]
  • Juan Zhong, Wangqiu Gong, Lu Lu, Jing Chen, Zibin Lu, HongYu Li, Wenting Liu, Yangyang Liu, Mingqing Wang, Rong Hu, Haibo Long, Lianbo Wei. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy. International immunopharmacology. 2017 Jan; 42(?):176-184. doi: 10.1016/j.intimp.2016.11.015. [PMID: 27919004]
  • S Afzal, M A Sattar, Edward J Johns, Mohammed H Abdulla, Safia Akhtar, Fayyaz Hashmi, Nor Azizan Abdullah. Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats. Journal of physiology and biochemistry. 2016 Dec; 72(4):593-604. doi: 10.1007/s13105-016-0497-1. [PMID: 27405250]
  • Margarida Mendes, Julie Dubourg, Anne Blanchard, Damien Bergerot, Pierre-Yves Courand, Valentina Forni, Michael Frank, Guillaume Bobrie, Joel Menard, Michel Azizi. Copeptin is increased in resistant hypertension. Journal of hypertension. 2016 12; 34(12):2458-2464. doi: 10.1097/hjh.0000000000001106. [PMID: 27755389]
  • Xiaolu Bao, Weibo Zhu, Weidong Yuan, Xingbo Zhu, Yijia Yan, Hesheng Tang, Zhilong Chen. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists. European journal of medicinal chemistry. 2016 Nov; 123(?):115-127. doi: 10.1016/j.ejmech.2016.07.023. [PMID: 27474928]
  • Shuang Li, Ke Wang, Guofang Xu, Jia Ji, Chuan Qin. The intervention effect of zinc supplementation on irbesartan treatment for atherosclerosis of ApoE-/- mice. Pakistan journal of pharmaceutical sciences. 2016 Nov; 29(6):1907-1912. doi: . [PMID: 28375105]
  • Frederik Persson, Simone Theilade, Jesper Eugen-Olsen, Peter Rossing, Hans-Henrik Parving. Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. Journal of diabetes and its complications. 2016 Nov; 30(8):1440-1442. doi: 10.1016/j.jdiacomp.2016.07.003. [PMID: 27475262]
  • Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J Gonzalez, Toshifumi Aoyama. Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan. Clinical science (London, England : 1979). 2016 11; 130(21):1969-1981. doi: 10.1042/cs20160343. [PMID: 27496805]
  • Jiashun Zeng, Qiong Wen, Rong Rong, Fengxian Huang, Qiongqiong Yang, Xueqing Tang, Feng He, Naya Huang, Xueqing Yu. Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy. Genetic testing and molecular biomarkers. 2016 Nov; 20(11):666-673. doi: 10.1089/gtmb.2016.0070. [PMID: 27603418]
  • Charalampos I Liakos, Gregory P Vyssoulis, Maria I Markou, Nikolaos V Kafkas, Konstantinos P Toutouzas, Dimitrios Tousoulis. Twenty-Four-Hour Urine α1 -Microglobulin as a Marker of Hypertension-Induced Renal Impairment and Its Response on Different Blood Pressure-Lowering Drugs. Journal of clinical hypertension (Greenwich, Conn.). 2016 10; 18(10):1000-1006. doi: 10.1111/jch.12811. [PMID: 26992096]
  • Matem Tunçdemir, Melek Öztürk. Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy. Metabolism: clinical and experimental. 2016 10; 65(10):1466-77. doi: 10.1016/j.metabol.2016.06.010. [PMID: 27621182]
  • Tobias Felix Kröpelin, Dick de Zeeuw, Frank Arjan Holtkamp, David Kenneth Packham, Hiddo J L Heerspink. Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2016 09; 31(9):1471-7. doi: 10.1093/ndt/gfv429. [PMID: 26790449]
  • Jing Ge, Jun-Jun Miao, Xin-Yi Sun, Jiang-Yi Yu. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. Journal of ethnopharmacology. 2016 Aug; 189(?):238-49. doi: 10.1016/j.jep.2016.05.033. [PMID: 27224243]